Denmaki -
Kidenmaki -
Lægemiddelstyrelsen (Danish Medicines Agency)
ritalin uno 30 mg kapsler med modificeret udløsning, hårde
infectopharm gmbh - methylphenidathydrochlorid - kapsler med modificeret udløsning, hårde - 30 mg
Denmaki -
Kidenmaki -
Lægemiddelstyrelsen (Danish Medicines Agency)
ritalin uno 40 mg kapsler med modificeret udløsning, hårde
infectopharm gmbh - methylphenidathydrochlorid - kapsler med modificeret udløsning, hårde - 40 mg
Denmaki -
Kidenmaki -
Lægemiddelstyrelsen (Danish Medicines Agency)
ritalin uno 60 mg kapsler med modificeret udløsning, hårde
infectopharm gmbh - methylphenidathydrochlorid - kapsler med modificeret udløsning, hårde - 60 mg
Denmaki -
Kidenmaki -
Lægemiddelstyrelsen (Danish Medicines Agency)
nalpain 10 mg/ml injektionsvæske, opløsning
orpha devel handels- und vertr. - nalbuphinhydrochlorid - injektionsvæske, opløsning - 10 mg/ml
Umoja wa Ulaya -
Kidenmaki -
EMA (European Medicines Agency)
enhertu
daiichi sankyo europe gmbh - trastuzumab deruxtecan - bryst neoplasmer - antineoplastiske midler - breast cancerher2-positive breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received one or more prior anti-her2-based regimens. her2-low breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4. non-small cell lung cancer (nsclc)enhertu as monotherapy is indicated for the treatment of adult patients with advanced nsclc whose tumours have an activating her2 (erbb2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. gastric cancerenhertu as monotherapy is indicated for the treatment of adult patients with advanced her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen.
Denmaki -
Kidenmaki -
Lægemiddelstyrelsen (Danish Medicines Agency)
tapentadol "teva" 100 mg depottabletter
teva gmbh - tapentadolphosphat - depottabletter - 100 mg
Denmaki -
Kidenmaki -
Lægemiddelstyrelsen (Danish Medicines Agency)
tapentadol "teva" 150 mg depottabletter
teva gmbh - tapentadolphosphat - depottabletter - 150 mg
Denmaki -
Kidenmaki -
Lægemiddelstyrelsen (Danish Medicines Agency)
tapentadol "teva" 200 mg depottabletter
teva gmbh - tapentadolphosphat - depottabletter - 200 mg
Denmaki -
Kidenmaki -
Lægemiddelstyrelsen (Danish Medicines Agency)
tapentadol "teva" 50 mg depottabletter
teva gmbh - tapentadolphosphat - depottabletter - 50 mg
Denmaki -
Kidenmaki -
SEGES Landbrug & Fødevarer
mospilan sg vandopløseligt granulat
nisso chemical europe gmbh - acetamiprid - vandopløseligt granulat - 200 g/kg acetamiprid